drugset / Trial / NCT02725541
Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer
Phase 2
Withdrawn
Jenny C. Chang, MD
Genentech, Inc. · collabThe Methodist Hospital Research Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, neoadjuvant phase II study to evaluate the objective response, toxicity, and safety of trastuzumab emtansine in patients with newly diagnosed HER2-equivocal breast cancer. Trastuzumab emtansine at a dose of 3.6 mg/kg will be intravenously administered every 3 weeks for a total of 6 weeks. Patients who achieve a partial or complete response after the 6-week treatment (responders) will continue on trastuzumab emtansine for an additional 12 weeks.
Timeline
- Start
- 2016-03
- Primary completion
- 2019-04
- Completion
- 2019-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab emtansine | Other / unclassified | 3.6 mg/kg | Intravenous |